DK166675B1 - Mycophenolsyrederivater, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse samt anvendelse af disse derivater til fremstilling af et laegemiddel - Google Patents

Mycophenolsyrederivater, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse samt anvendelse af disse derivater til fremstilling af et laegemiddel Download PDF

Info

Publication number: DK166675B1
Authority: DK; Denmark
Prior art keywords: formula; compound; methyl; pharmaceutically acceptable; hydrogen
Prior art date: 1987-01-30

Application number

DK658787A

Other languages

Danish (da)

English (en)

Other versions

DK658787A (da

DK658787D0 (da

Inventor

Peter H Nelson

Chee-Liang Leo Gu

Anthony C Allison

Elsie M Eugui

William A Lee

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-01-30

Filing date

1987-12-15

Publication date

1993-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21733252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK166675(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-12-15 Application filed by Syntex Inc filed Critical Syntex Inc

1987-12-15 Publication of DK658787D0 publication Critical patent/DK658787D0/da

1988-07-31 Publication of DK658787A publication Critical patent/DK658787A/da

1993-06-28 Application granted granted Critical

1993-06-28 Publication of DK166675B1 publication Critical patent/DK166675B1/da

Links

HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical class OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title claims description 34
238000004519 manufacturing process Methods 0.000 title claims description 5
238000000034 method Methods 0.000 title description 37
238000002360 preparation method Methods 0.000 title description 26
239000000825 pharmaceutical preparation Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 155
150000003839 salts Chemical class 0.000 claims abstract description 35
125000000217 alkyl group Chemical group 0.000 claims abstract description 32
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
239000001257 hydrogen Substances 0.000 claims abstract description 23
125000003118 aryl group Chemical group 0.000 claims abstract description 20
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
-1 acyl anhydride Chemical class 0.000 claims description 45
239000002253 acid Substances 0.000 claims description 27
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
150000001718 carbodiimides Chemical class 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
125000004122 cyclic group Chemical group 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 claims description 6
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical group 0.000 claims description 5
241000700605 Viruses Species 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
231100000252 nontoxic Toxicity 0.000 claims description 4
230000003000 nontoxic effect Effects 0.000 claims description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
150000001266 acyl halides Chemical class 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
229910014033 C-OH Inorganic materials 0.000 claims 1
229910014570 C—OH Inorganic materials 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
230000001185 psoriatic effect Effects 0.000 claims 1
229940121363 anti-inflammatory agent Drugs 0.000 abstract description 4
239000002260 anti-inflammatory agent Substances 0.000 abstract description 4
239000003795 chemical substances by application Substances 0.000 abstract description 4
239000003018 immunosuppressive agent Substances 0.000 abstract description 4
239000002246 antineoplastic agent Substances 0.000 abstract description 3
239000003443 antiviral agent Substances 0.000 abstract description 3
230000002682 anti-psoriatic effect Effects 0.000 abstract description 2
229940125721 immunosuppressive agent Drugs 0.000 abstract description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 28
229960000951 mycophenolic acid Drugs 0.000 description 28
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 22
239000000203 mixture Substances 0.000 description 21
239000000243 solution Substances 0.000 description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
238000012360 testing method Methods 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 12
125000000753 cycloalkyl group Chemical group 0.000 description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
239000002585 base Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
DZCBKUAAGVVLOX-UHFFFAOYSA-N 1-morpholin-4-ylethanol Chemical compound CC(O)N1CCOCC1 DZCBKUAAGVVLOX-UHFFFAOYSA-N 0.000 description 7
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
229910052760 oxygen Inorganic materials 0.000 description 7
239000001301 oxygen Substances 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
239000003960 organic solvent Substances 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
229920002684 Sepharose Polymers 0.000 description 5
238000003556 assay Methods 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
239000012467 final product Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000001506 immunosuppresive effect Effects 0.000 description 5
239000003226 mitogen Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 5
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
125000002252 acyl group Chemical group 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000008101 lactose Substances 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
239000003921 oil Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000008272 agar Substances 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000032050 esterification Effects 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
150000004820 halides Chemical class 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
238000002955 isolation Methods 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000006187 pill Substances 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
230000008961 swelling Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
JVLRWCNKOZTQEQ-FZSIALSZSA-N 2-morpholin-4-ylethyl (e)-6-(4-acetyloxy-6-methoxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(OC(C)=O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 JVLRWCNKOZTQEQ-FZSIALSZSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
239000004255 Butylated hydroxyanisole Substances 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
241000186359 Mycobacterium Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
235000011054 acetic acid Nutrition 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
238000007098 aminolysis reaction Methods 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
230000003602 anti-herpes Effects 0.000 description 2
210000000628 antibody-producing cell Anatomy 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
229940030999 antipsoriatics Drugs 0.000 description 2
239000008135 aqueous vehicle Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
229940043253 butylated hydroxyanisole Drugs 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
125000004663 dialkyl amino group Chemical group 0.000 description 2
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
125000001188 haloalkyl group Chemical group 0.000 description 2
230000002949 hemolytic effect Effects 0.000 description 2
208000010726 hind limb paralysis Diseases 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
229960003444 immunosuppressant agent Drugs 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
150000007530 organic bases Chemical group 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
RLDKNPYCJCTBJA-KPKJPENVSA-N (E)-6-[4-(2,2-dimethylpropanoyloxy)-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl]-4-methylhex-4-enoic acid Chemical compound CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)OC(=O)C(C)(C)C RLDKNPYCJCTBJA-KPKJPENVSA-N 0.000 description 1
IESYHSYFTWWOGF-RUDMXATFSA-N (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoyl chloride Chemical compound OC1=C(C\C=C(/C)CCC(Cl)=O)C(OC)=C(C)C2=C1C(=O)OC2 IESYHSYFTWWOGF-RUDMXATFSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
BOSWPVRACYJBSJ-UHFFFAOYSA-N 1,3-di(p-tolyl)carbodiimide Chemical compound C1=CC(C)=CC=C1N=C=NC1=CC=C(C)C=C1 BOSWPVRACYJBSJ-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241000283086 Equidae Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
RZKYEQDPDZUERB-UHFFFAOYSA-N Pindone Chemical group C1=CC=C2C(=O)C(C(=O)C(C)(C)C)C(=O)C2=C1 RZKYEQDPDZUERB-UHFFFAOYSA-N 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
231100000460 acute oral toxicity Toxicity 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000947 anti-immunosuppressive effect Effects 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
210000001142 back Anatomy 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
AQIHMSVIAGNIDM-UHFFFAOYSA-N benzoyl bromide Chemical compound BrC(=O)C1=CC=CC=C1 AQIHMSVIAGNIDM-UHFFFAOYSA-N 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000007073 chemical hydrolysis Effects 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000021552 granulated sugar Nutrition 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
238000002962 plaque-reduction assay Methods 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000004144 purine metabolism Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000003501 vero cell Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Furan Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)

DK658787A 1987-01-30 1987-12-15 Mycophenolsyrederivater, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse samt anvendelse af disse derivater til fremstilling af et laegemiddel DK166675B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US871787		1987-01-30
US07/008,717 US4753935A (en)	1987-01-30	1987-01-30	Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Publications (3)

Publication Number	Publication Date
DK658787D0 DK658787D0 (da)	1987-12-15
DK658787A DK658787A (da)	1988-07-31
DK166675B1 true DK166675B1 (da)	1993-06-28

Family

ID=21733252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK658787A DK166675B1 (da)	1987-01-30	1987-12-15	Mycophenolsyrederivater, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse samt anvendelse af disse derivater til fremstilling af et laegemiddel

Country Status (26)

Country	Link
US (7)	US4753935A (fr)
EP (1)	EP0281713B1 (fr)
JP (1)	JPS63188672A (fr)
KR (1)	KR940003758B1 (fr)
AT (1)	ATE68180T1 (fr)
AU (1)	AU599728B2 (fr)
CA (1)	CA1333285C (fr)
DE (2)	DE19675020I2 (fr)
DK (1)	DK166675B1 (fr)
ES (1)	ES2038190T3 (fr)
FI (1)	FI85141C (fr)
GE (1)	GEP20094816B (fr)
GR (1)	GR3002866T3 (fr)
HK (1)	HK125893A (fr)
HU (2)	HU201927B (fr)
IE (1)	IE60750B1 (fr)
IL (1)	IL84833A (fr)
LU (1)	LU88795I2 (fr)
LV (1)	LV5748B4 (fr)
MX (1)	MX9203163A (fr)
NL (1)	NL960019I2 (fr)
NO (2)	NO171680C (fr)
NZ (1)	NZ222922A (fr)
PH (1)	PH23819A (fr)
PT (1)	PT86343B (fr)
ZA (1)	ZA879414B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5177072A (en) *	1987-01-30	1993-01-05	Syntex (U.S.A.) Inc.	Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
AU632796B2 (en) *	1989-02-23	1993-01-14	University Of North Carolina At Chapel Hill, The	Etoposide analogues
US5219851A (en) *	1991-03-05	1993-06-15	Warner-Lambert Company	Tetrahydroisoquinoline-type renin inhibiting peptides
US5247083A (en) *	1992-07-10	1993-09-21	Syntex (U.S.A.) Inc.	Direct esterification of mycophenolic acid
WO1994012184A1 (fr) *	1992-11-24	1994-06-09	Syntex (U.S.A.) Inc.	Utilisation d'acide mycophenolique, de mofetile de mycophenolate ou d'un derive de ceux-ci pour inhiber la stenose
US5455045A (en) *	1993-05-13	1995-10-03	Syntex (U.S.A.) Inc.	High dose formulations
PL176595B1 (pl) *	1993-06-25	1999-06-30	Main Camp Marketing Pty Ltd	Środek leczniczy w postaci koncentratu z nasion selera i sposób otrzymywania środka leczniczego w postaci koncentratu z nasion selera
JP3411038B2 (ja) *	1993-09-15	2003-05-26	シンテックス（ユー・エス・エイ）・インコーポレイテッド	ミコフェノール酸モフェチルの結晶質無水物およびその静注用製剤
EP1475091A1 (fr) *	1993-10-01	2004-11-10	Roche Palo Alto LLC	Suspensions de mycophénolate mofetile à dosage élevé et administration orale
US5493030A (en) *	1994-02-18	1996-02-20	Syntex (U.S.A.) Inc.	5-substituted derivatives of mycophenolic acid
US5444072A (en) *	1994-02-18	1995-08-22	Syntex (U.S.A.) Inc.	6-substituted mycophenolic acid and derivatives
US5380879A (en) *	1994-02-18	1995-01-10	Syntex (U.S.A.) Inc.	Derivatives of mycophenolic acid
US5512568A (en) *	1994-02-18	1996-04-30	Syntex (U.S.A.) Inc.	Method of using 4-amino derivatives of 5-substituted mycophenolic acid
US5525602A (en) *	1994-02-18	1996-06-11	Syntex (U.S.A.) Inc.	Method of using 4-amino 6-substituted mycophenolic acid and derivatives
US6225073B1 (en)	1994-07-07	2001-05-01	Dade Behring Marburg Gmbh	Immunoassay for mycophenolic acid
ID18663A (id) *	1996-04-12	1998-04-30	Novartis Ag	Komposisi farmasi berlapis enterik
WO2000025780A1 (fr)	1998-10-29	2000-05-11	Bristol-Myers Squibb Company	Composes derives d'un noyau amine inhibiteurs de l'enzyme impdh
US6420403B1 (en)	1998-10-29	2002-07-16	Edwin J. Iwanowicz	Inhibitors of IMPDH enzyme
US6596747B2 (en)	1998-10-29	2003-07-22	Bristol-Myers Squibb Company	Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
CA2348267A1 (fr) *	1998-10-29	2000-05-11	Henry H. Gu	Nouveaux inhibiteurs de l'enzyme impdh
IN188985B (fr)	1998-12-09	2002-11-30	Biocon Ltd
US6514979B1 (en)	1999-03-03	2003-02-04	University Of Maryland Biotechnology Institute	Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
US6107052A (en) *	1999-06-09	2000-08-22	Roche Diagnostics Corporation	Enzymatic measurement of mycophenolic acid
AU5553801A (en) *	2000-04-24	2001-11-07	Bristol Myers Squibb Co	Heterocycles that are inhibitors of impdh enzyme
US6471980B2 (en)	2000-12-22	2002-10-29	Avantec Vascular Corporation	Intravascular delivery of mycophenolic acid
US7179791B2 (en) *	2001-01-11	2007-02-20	Duke University	Inhibiting GS-FDH to modulate NO bioactivity
GB0124953D0 (en) *	2001-10-17	2001-12-05	Novartis Ag	Organic Compounds
TW200301698A (en) *	2001-12-21	2003-07-16	Bristol Myers Squibb Co	Acridone inhibitors of IMPDH enzyme
EP2316468A1 (fr)	2002-02-22	2011-05-04	Shire LLC	Système de distribution et méthodes de protection et d'administration de dextroamphetamine
AU2003261354A1 (en) *	2002-08-02	2004-02-23	The Regents Of The University Of California	New uses for inhibitors of inosine monophosphate dehydrogenase
TWI221414B (en) *	2003-02-21	2004-10-01	Chunghwa Chemical Synthesis &	Method of making mycophenolate mofetil using transesterification
GB0307553D0 (en) *	2003-04-01	2003-05-07	Novartis Ag	Organic compounds
AU2003231924A1 (en) *	2003-04-07	2004-11-01	Biocon Limited	Microwave synthesis of mycophenolate
WO2004100945A1 (fr) *	2003-05-14	2004-11-25	Dsm Ip Assets B.V.	Utilisation de derives phtalides pour assurer le traitement et la prophylaxie du diabete sucre
US20050187170A1 (en) *	2003-06-16	2005-08-25	Biocryst Pharmaceuticals, Inc.	Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
DE602004015310D1 (de) *	2003-09-11	2008-09-04	Sandoz Ag	Verfahren zur herstellung von mycophenolatmofetil
CN100518733C (zh) *	2003-09-23	2009-07-29	帝斯曼知识产权资产管理有限公司	用于治疗和预防糖尿病的组合物
AU2003272083A1 (en) *	2003-10-07	2005-04-21	Biocon Limited	Salt of 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid with n, n-dimethyl-imidodicarbonimidic diamide
MXPA06005659A (es) *	2004-04-26	2007-04-10	Teva Gyogyszergyar Zartkoruen	Proceso para preparacion de acido micofenolico y derivados de ester del mismo.
EP1740563A2 (fr) *	2004-04-27	2007-01-10	Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság	Impureté du mofétilmycophénolate
WO2006115509A2 (fr)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
US7439373B2 (en) *	2004-07-20	2008-10-21	TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság	Crystalline mycophenolate sodium
CA2577169A1 (fr) *	2004-08-16	2006-02-23	The University Of Queensland	Agents de modulation du metabolisme et utilisations associees
WO2006076802A1 (fr) *	2005-01-20	2006-07-27	Apotex Fermentation Inc.	Procede ameliore de preparation de mycophenolate mofetil
EP1917010A2 (fr) *	2005-02-08	2008-05-07	Aspreva Pharmaceuticals SA	Compositions et methodes pour traiter des maladies vasculaires, auto-immunes et inflammatoires
US20060235009A1 (en) *	2005-02-08	2006-10-19	Richard Glickman	Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
US20080281111A1 (en) *	2005-04-26	2008-11-13	Sandor Molnar	Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CN100402516C (zh) *	2005-10-18	2008-07-16	深圳市东阳光实业发展有限公司	一种霉酚酸莫啡酯的制备方法
US20090023805A1 (en) *	2006-02-13	2009-01-22	Anne Claire Marrast	Method of administration
WO2008003637A2 (fr) *	2006-07-05	2008-01-10	Dsm Ip Assets B.V.	Isolation et utilisation de sels aminés d'acide mycophénolique
WO2008033466A2 (fr) *	2006-09-14	2008-03-20	Combinatorx (Singapore) Pre. Ltd.	Compositions et procédés pour le traitement de maladies virales
US20080188653A1 (en) *	2007-02-04	2008-08-07	Formosa Laboratories, Inc.	Process for Preparation of Mycophenolate Mofetil
CN100484930C (zh) *	2007-03-16	2009-05-06	重庆大新药业股份有限公司	一种吗替麦考酚酯的制备方法
WO2009000834A1 (fr) *	2007-06-27	2008-12-31	Dsm Ip Assets B.V.	Procédé de purification de mycophénolate mofétil
WO2009010503A1 (fr) *	2007-07-18	2009-01-22	Dsm Ip Assets B.V.	Recyclage d'acide mycophénolique dans un procédé de préparation de mycophénolate mofétil
US20090076000A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched mycophenolate mofetil
TW200932240A (en)	2007-10-25	2009-08-01	Astellas Pharma Inc	Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
WO2009084008A1 (fr) *	2007-12-28	2009-07-09	Cadila Healthcare Limited	Procédé de préparation de mycophénolate mofétil
KR100975520B1 (ko) *	2008-02-01	2010-08-12	종근당바이오 주식회사	마이코페놀레이트 모페틸의 개선된 제조방법
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
EP2310008A4 (fr) *	2008-07-09	2014-03-05	Aspreva Internat Ltd	Solutions de l'acide mycophenolique de sodium a ph specifiques pour le traitement de troubles oculaires
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
NZ593649A (en) *	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Nucleoside analogs
PA8855601A1 (es)	2008-12-23	2010-07-27		Forformidatos de nucleósidos
FI124873B (fi)	2009-10-06	2015-02-27	Maricap Oy	Menetelmä ja laitteisto pneumaattisessa materiaalinsiirtojärjestelmässä
FI20096026A7 (fi)	2009-10-06	2011-04-07	Maricap Oy	Menetelmä ja laitteisto pneumaattisessa materiaalinsiirtojärjestelmässä
SG184324A1 (en)	2010-03-31	2012-11-29	Gilead Pharmasset Llc	Nucleoside phosphoramidates
GB201100786D0 (en)	2011-01-18	2011-03-02	Ems Sa	Pharmaceutical compositions of immunosuppressants
CN102952105A (zh) *	2011-08-26	2013-03-06	中国科学院上海药物研究所	一类霉酚酸衍生物、其制备方法和用途
WO2013041205A1 (fr)	2011-09-19	2013-03-28	Pyxirion Pharma Gmbh	Nouveaux concepts thérapeutiques pour le traitement de maladies vasculaires
KR102085557B1 (ko)	2013-03-14	2020-03-06	엘커메스 파마 아일랜드 리미티드	푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
US8669281B1 (en)	2013-03-14	2014-03-11	Alkermes Pharma Ireland Limited	Prodrugs of fumarates and their use in treating various diseases
US10369133B2 (en)	2013-07-23	2019-08-06	The University Of Tennessee Research Foundation	Immunosuppressive compounds and therapeutics
WO2015105174A1 (fr) *	2014-01-10	2015-07-16	富士フイルム株式会社	Procédé de prédiction et dispositif de prédiction de dose efficace/sensibilité de 5-hydroxy-1h-imidazole-4-carboxamide, procédé de mesure de quantité de monophosphate de xanthosine, et agent de traitement et procédé de traitement de syndrome myélodysplasique
JP6337135B2 (ja)	2014-02-24	2018-06-06	アルカーメスファーマアイルランドリミテッド	フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US12011429B2 (en)	2016-06-02	2024-06-18	Steven Baranowitz	Prevention and treatment of viral infections
CA3026241A1 (fr)	2016-06-02	2017-12-07	Steven Baranowitz	Prevention et traitement d'infections virales
US10603299B2 (en)	2016-06-02	2020-03-31	Steven Baranowitz	Prevention and treatment of viral infections
WO2018167628A1 (fr)	2017-03-13	2018-09-20	Ftf Pharma Private Limited	Composition pharmaceutique de suspension orale d'agents immunosuppresseurs
US10835489B2 (en) *	2018-03-09	2020-11-17	University Of Saskatchewan	Modified release formulations of mycophenolate mofetil
WO2020039263A2 (fr)	2018-08-18	2020-02-27	Ftf Pharma Private Limited	Suspension pharmaceutique pour forme galénique orale
CN110526885A (zh) *	2019-08-20	2019-12-03	上海英诺富成生物科技有限公司	麦考酚酸的前体药物及其制备方法
CN113549040B (zh) *	2020-04-23	2024-08-06	鲁南制药集团股份有限公司	一种吗替麦考酚酯杂质d的制备方法
CN112121173B (zh) *	2020-08-22	2022-05-06	浙江大学	脂肪酸修饰的免疫抑制剂mmf及fk506纳米制剂及其制备方法和应用
WO2022187379A1 (fr)	2021-03-03	2022-09-09	Sana Biotechnology, Inc.	Thérapies immunosuppressives destinées à être utilisées avec des thérapies cellulaires à base de cardiomyocytes, et méthodes et compositions associées

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1157100A (en) *	1966-09-27	1969-07-02	Ici Ltd	Pharmaceutical Compositions
GB1173942A (en) *	1967-06-06	1969-12-10	Bellon Labor Sa Roger	New 2,3-Dihydro-1,4-Benzoxazines
GB1261060A (en) *	1969-09-09	1972-01-19	Ici Ltd	Phthalen-1-one derivatives
US3825571A (en) *	1971-07-31	1974-07-23	Chugai Pharmaceutical Co Ltd	Mycophenolic acid derivatives
JPS5542995B2 (fr) *	1972-02-24	1980-11-04
JPS5529994B2 (fr) *	1972-03-02	1980-08-07
JPS563353B2 (fr) *	1972-03-02	1981-01-24
US3868454A (en) *	1972-08-14	1975-02-25	Lilly Co Eli	Psoriasis treatment with mycophenolic acid derivatives
US3777020A (en) *	1972-08-14	1973-12-04	Lilly Co Eli	Psoriasis treatment with mycophenolic acid
US3880995A (en) *	1973-05-14	1975-04-29	Lilly Co Eli	Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) *	1973-05-22	1975-09-02	Lilly Co Eli	Mycophenolic acid derivatives
US3905894A (en) *	1973-10-02	1975-09-16	Murskauskone Oy	Apparatus for wet fine screening
JPS5724380A (en) *	1980-07-22	1982-02-08	Chugai Pharmaceut Co Ltd	Preparation of mycophenolic acid derivative
JPS57183776A (en) *	1981-05-01	1982-11-12	Ajinomoto Co Inc	Preparation of mycophenolic acid derivative
JPS57183777A (en) *	1981-05-01	1982-11-12	Ajinomoto Co Inc	Preparation of mycophenolic acid derivative
IT1150194B (it) *	1982-02-23	1986-12-10	Chiesi Farma Spa	Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva

1987
- 1987-01-30 US US07/008,717 patent/US4753935A/en not_active Expired - Lifetime
- 1987-09-04 US US07/093,459 patent/US4808592A/en not_active Expired - Lifetime
- 1987-12-11 PT PT86343A patent/PT86343B/pt active IP Right Revival
- 1987-12-15 ES ES198787311021T patent/ES2038190T3/es not_active Expired - Lifetime
- 1987-12-15 AU AU82540/87A patent/AU599728B2/en not_active Expired
- 1987-12-15 IL IL84833A patent/IL84833A/xx not_active IP Right Cessation
- 1987-12-15 DE DE1996175020 patent/DE19675020I2/de active Active
- 1987-12-15 PH PH36232A patent/PH23819A/en unknown
- 1987-12-15 ZA ZA879414A patent/ZA879414B/xx unknown
- 1987-12-15 DE DE8787311021T patent/DE3773660D1/de not_active Expired - Lifetime
- 1987-12-15 AT AT87311021T patent/ATE68180T1/de active
- 1987-12-15 LU LU88795C patent/LU88795I2/fr unknown
- 1987-12-15 FI FI875502A patent/FI85141C/fi not_active IP Right Cessation
- 1987-12-15 CA CA000554352A patent/CA1333285C/fr not_active Expired - Lifetime
- 1987-12-15 HU HU875663A patent/HU201927B/hu unknown
- 1987-12-15 EP EP87311021A patent/EP0281713B1/fr not_active Expired - Lifetime
- 1987-12-15 NO NO875240A patent/NO171680C/no not_active IP Right Cessation
- 1987-12-15 NZ NZ222922A patent/NZ222922A/xx unknown
- 1987-12-15 KR KR1019870014353A patent/KR940003758B1/ko not_active Expired - Lifetime
- 1987-12-15 JP JP62320066A patent/JPS63188672A/ja active Granted
- 1987-12-15 DK DK658787A patent/DK166675B1/da not_active IP Right Cessation
- 1987-12-15 IE IE339787A patent/IE60750B1/en not_active IP Right Cessation
1988
- 1988-01-22 US US07/146,883 patent/US4786637A/en not_active Expired - Lifetime
- 1988-08-17 US US07/233,200 patent/US4868153A/en not_active Expired - Lifetime
- 1988-11-14 US US07/272,161 patent/US4952579A/en not_active Expired - Lifetime
1989
- 1989-06-29 US US07/373,413 patent/US4948793A/en not_active Expired - Lifetime
1990
- 1990-03-28 US US07/500,439 patent/US4992467A/en not_active Expired - Lifetime
1991
- 1991-10-10 GR GR91400377T patent/GR3002866T3/el unknown
1992
- 1992-06-23 MX MX9203163A patent/MX9203163A/es unknown
1993
- 1993-11-11 HK HK1258/93A patent/HK125893A/en not_active IP Right Cessation
1994
- 1994-07-01 HU HU94P/P00008P patent/HU210350A9/hu unknown
1996
- 1996-07-05 LV LV960221A patent/LV5748B4/xx unknown
- 1996-07-12 NL NL960019C patent/NL960019I2/nl unknown
1997
- 1997-07-01 NO NO1997007C patent/NO1997007I1/no unknown
2006
- 2006-07-17 GE GEAP19879526A patent/GEP20094816B/en unknown

Also Published As

Publication number	Publication date
NO171680B (no)	1993-01-11
ES2038190T3 (es)	1993-07-16
NZ222922A (en)	1990-09-26
ATE68180T1 (de)	1991-10-15
IE60750B1 (en)	1994-08-10
HU210350A9 (en)	1995-03-28
FI875502A0 (fi)	1987-12-15
LV5748B4 (lv)	1997-02-20
US4753935A (en)	1988-06-28
KR880009016A (ko)	1988-09-13
PH23819A (en)	1989-11-23
DE3773660D1 (de)	1991-11-14
EP0281713A1 (fr)	1988-09-14
NO1997007I1 (no)	1997-07-01
PT86343B (pt)	1991-02-08
US4786637A (en)	1988-11-22
NO875240L (no)	1988-08-01
US4808592A (en)	1989-02-28
NL960019I1 (nl)	1996-10-01
NO875240D0 (no)	1987-12-15
NL960019I2 (nl)	1997-06-02
IE873397L (en)	1988-07-30
AU599728B2 (en)	1990-07-26
HUT47567A (en)	1989-03-28
CA1333285C (fr)	1994-11-29
KR940003758B1 (ko)	1994-04-30
AU8254087A (en)	1988-08-04
EP0281713B1 (fr)	1991-10-09
US4952579A (en)	1990-08-28
IL84833A0 (en)	1988-06-30
GR3002866T3 (en)	1993-01-25
ZA879414B (en)	1989-08-30
LU88795I2 (fr)	1996-11-05
DE19675020I2 (de)	2002-11-07
HU201927B (en)	1991-01-28
US4868153A (en)	1989-09-19
DK658787A (da)	1988-07-31
GEP20094816B (en)	2009-11-10
IL84833A (en)	1992-03-29
LV5748A4 (lv)	1996-10-20
FI875502L (fi)	1988-07-31
PT86343A (en)	1988-01-01
JPS63188672A (ja)	1988-08-04
FI85141B (fi)	1991-11-29
FI85141C (fi)	1992-03-10
US4948793A (en)	1990-08-14
MX9203163A (es)	1992-07-31
NO171680C (no)	1993-04-21
HK125893A (en)	1993-11-19
US4992467A (en)	1991-02-12
JPH0571591B2 (fr)	1993-10-07
DK658787D0 (da)	1987-12-15

Legal Events

Date	Code	Title	Description
2008-01-02	PUP	Patent expired

Publication	Publication Date	Title
DK166675B1 (da)	1993-06-28	Mycophenolsyrederivater, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat indeholdende disse samt anvendelse af disse derivater til fremstilling af et laegemiddel
US4727069A (en)	1988-02-23	Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4861776A (en)	1989-08-29	Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof, compositions and use
US5441953A (en)	1995-08-15	4- amino derivatives of mycophenolic acid
US4748173A (en)	1988-05-31	Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions
KR910002883B1 (ko)	1991-05-09	벤조푸란-또는 벤조피란-카르복사미드 유도체의 제조방법
US4725622A (en)	1988-02-16	Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4686234A (en)	1987-08-11	Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
JPH05238974A (ja)	1993-09-17	ベンゾ［ａフルオレン化合物
KR100513302B1 (ko)	2005-11-11	3-아미노-1,2-벤조이소옥사졸 유도체, 이의 제조방법및 용도
KR850000216B1 (ko)	1985-03-06	피페라진 유도체의 제조방법
US4749701A (en)	1988-06-07	Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same
US4435422A (en)	1984-03-06	5-Substituted 2,3-dihydrobenzofuran-2-carboxylic acids and their use in diuretic compositions
CS196305B2 (en)	1980-03-31	Process for preparing derivatives of benzophenones
US5177072A (en)	1993-01-05	Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
KR900004829B1 (ko)	1990-07-07	치환된 1,8-나프티리딘온 및 이의 제조방법
US4228166A (en)	1980-10-14	2-Keto-4,5-dihydro-3 (2H)-pyridazinones, and their use in treating muscle tension
GB2186570A (en)	1987-08-19	9,10-dihydro-phenanthrene derivatives
CN121895267A (zh)	2026-04-21	一种9位去甲基抗肾纤维化天然产物Commiphorane C-D、异构体其制法与用途
EP0141884B1 (fr)	1988-07-20	Dérivés de phénylpipérazine, procédé de préparation et compositions pharmaceutiques les contenant
JPH0157114B2 (fr)	1989-12-04